Randomized Multicentric(隨機多中心)到底是什麼？
Randomized Multicentric 隨機多中心 - Methods A non-randomized multicentric case-series retrospective study was developed. [1] More large randomized multicentric studies of good quality and less bias are needed to test whether PRP injections can be used as a routine treatment option in management of patients with Osteoarthritis of knee. [2] However, despite increasing efforts to identify early predictors of cardiotoxicity and growing evidence of the importance of cardiac biomarkers for this purpose, large randomized multicentric clinical trials are still lacking and so there is still no scientific agreement on the best approach for early diagnosis. [3] There is still a need for randomized multicentric clinical trials to further substantiate and clarify reports from epidemiological studies. [4] DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Twenty-eight participants from the NICE cohort received two infusions of 1-g rituximab at two-week intervals, whereas 27 participants from the Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Membranous Nephropathy (GEMRITUX) cohort received two infusions of 375 mg/m2 at one-week interval. [5] This prospective randomized multicentric clinical trial will test low titer group O whole blood to components therapy in the in-hospital management of trauma patients with massive hemorrhage. [6] Patients-method This is a prospective, randomized multicentric study. [7] The lack of randomized multicentric study, implies the management of ACCL by skilled multidisciplinary team, to suggest adequate personalized treatment. [8] A drawback for interpretation of current data is the fact that they rely on case series and reports and are not validated through more powerful randomized multicentric trials. [9] Limitations to the routine use of CPET are mainly represented from the lack of measurement standardization and limited data from randomized multicentric studies. [10]方法進行了一項非隨機多中心病例係列回顧性研究。 [1] 需要更多高質量和較少偏倚的大型隨機多中心研究來測試 PRP 注射是否可以作為膝關節骨性關節炎患者管理的常規治療選擇。 [2] 然而，儘管越來越多地努力識別心臟毒性的早期預測因子，並且越來越多的證據表明心臟生物標誌物對此目的的重要性，但仍然缺乏大型隨機多中心臨床試驗，因此對於早期診斷的最佳方法仍然沒有科學共識。 [3] 仍然需要進行隨機多中心臨床試驗，以進一步證實和澄清流行病學研究的報告。 [4] 設計、設置、參與者和測量 來自 NICE 隊列的 28 名參與者每隔兩週接受兩次 1-g 利妥昔單抗輸注，而來自前瞻性隨機多中心開放標籤研究評估利妥昔單抗治療膜性腎病 (GEMRITUX) 隊列的 27 名參與者接受兩次 375 mg 輸注/m2 間隔一周。 [5] 這項前瞻性隨機多中心臨床試驗將測試低滴度 O 組全血成分治療在大出血創傷患者的院內管理中的作用。 [6] 患者方法 這是一項前瞻性、隨機的多中心研究。 [7] 缺乏隨機多中心研究，意味著 ACCL 由熟練的多學科團隊管理，以建議充分的個性化治療。 [8] 解釋當前數據的一個缺點是它們依賴於案例係列和報告，並且沒有通過更強大的隨機多中心試驗進行驗證。 [9] 常規使用 CPET 的局限性主要體現在缺乏測量標準化和隨機多中心研究的數據有限。 [10]
Prospective Randomized Multicentric
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Twenty-eight participants from the NICE cohort received two infusions of 1-g rituximab at two-week intervals, whereas 27 participants from the Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Membranous Nephropathy (GEMRITUX) cohort received two infusions of 375 mg/m2 at one-week interval. [1] This prospective randomized multicentric clinical trial will test low titer group O whole blood to components therapy in the in-hospital management of trauma patients with massive hemorrhage. [2]設計、設置、參與者和測量 來自 NICE 隊列的 28 名參與者每隔兩週接受兩次 1-g 利妥昔單抗輸注，而來自前瞻性隨機多中心開放標籤研究評估利妥昔單抗治療膜性腎病 (GEMRITUX) 隊列的 27 名參與者接受兩次 375 mg 輸注/m2 間隔一周。 [1] 這項前瞻性隨機多中心臨床試驗將測試低滴度 O 組全血成分治療在大出血創傷患者的院內管理中的作用。 [2]
Large Randomized Multicentric 大型隨機多中心
More large randomized multicentric studies of good quality and less bias are needed to test whether PRP injections can be used as a routine treatment option in management of patients with Osteoarthritis of knee. [1] However, despite increasing efforts to identify early predictors of cardiotoxicity and growing evidence of the importance of cardiac biomarkers for this purpose, large randomized multicentric clinical trials are still lacking and so there is still no scientific agreement on the best approach for early diagnosis. [2]需要更多高質量和較少偏倚的大型隨機多中心研究來測試 PRP 注射是否可以作為膝關節骨性關節炎患者管理的常規治療選擇。 [1] 然而，儘管越來越多地努力識別心臟毒性的早期預測因子，並且越來越多的證據表明心臟生物標誌物對此目的的重要性，但仍然缺乏大型隨機多中心臨床試驗，因此對於早期診斷的最佳方法仍然沒有科學共識。 [2]
randomized multicentric study
More large randomized multicentric studies of good quality and less bias are needed to test whether PRP injections can be used as a routine treatment option in management of patients with Osteoarthritis of knee. [1] Patients-method This is a prospective, randomized multicentric study. [2] The lack of randomized multicentric study, implies the management of ACCL by skilled multidisciplinary team, to suggest adequate personalized treatment. [3] Limitations to the routine use of CPET are mainly represented from the lack of measurement standardization and limited data from randomized multicentric studies. [4]需要更多高質量和較少偏倚的大型隨機多中心研究來測試 PRP 注射是否可以作為膝關節骨性關節炎患者管理的常規治療選擇。 [1] 患者方法 這是一項前瞻性、隨機的多中心研究。 [2] 缺乏隨機多中心研究，意味著 ACCL 由熟練的多學科團隊管理，以建議充分的個性化治療。 [3] 常規使用 CPET 的局限性主要體現在缺乏測量標準化和隨機多中心研究的數據有限。 [4]
randomized multicentric clinical 隨機多中心臨床
However, despite increasing efforts to identify early predictors of cardiotoxicity and growing evidence of the importance of cardiac biomarkers for this purpose, large randomized multicentric clinical trials are still lacking and so there is still no scientific agreement on the best approach for early diagnosis. [1] There is still a need for randomized multicentric clinical trials to further substantiate and clarify reports from epidemiological studies. [2] This prospective randomized multicentric clinical trial will test low titer group O whole blood to components therapy in the in-hospital management of trauma patients with massive hemorrhage. [3]然而，儘管越來越多地努力識別心臟毒性的早期預測因子，並且越來越多的證據表明心臟生物標誌物對此目的的重要性，但仍然缺乏大型隨機多中心臨床試驗，因此對於早期診斷的最佳方法仍然沒有科學共識。 [1] 仍然需要進行隨機多中心臨床試驗，以進一步證實和澄清流行病學研究的報告。 [2] 這項前瞻性隨機多中心臨床試驗將測試低滴度 O 組全血成分治療在大出血創傷患者的院內管理中的作用。 [3]